UNSPSC 51263119: Cicloprolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C18H29NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1K2ACH4U3R, chemically known as 2-propanol, 1-(4-(2-(cyclopropylmethoxy)ethoxy)phenoxy)-3-((1-methylethyl)amino)- but generally known as cicloprolol, which bears US NIH Compound Identifier 146294. European Medicines Agency schedules Cicloprolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06248MIG.

UNSPSC 51263119 Cicloprolol is a Commodity code that captures pharmaceutical products purchased by state and local health agencies, though recent solicitation activity under this code shows limited alignment with the code's nominal scope. The single recent opportunity identifies Seminole County, Florida pursuing naloxone and drug deactivation systems—opioid-reversal medication and harm-reduction equipment rather than cicloprolol, a cardiovascular beta-blocker. State and local health departments, county community health agencies, and public safety entities use procurement codes in this family to source medications and medical countermeasures for emergency response, public health initiatives, and community health programs, but the cicloprolol code itself shows minimal recent activity grounded in its actual pharmaceutical classification.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. The bid deadline was July 26, 2023 (a discrepancy in the source dates suggests data integrity issues with the opportunity record). Vendors must provide unit pricing for each line item, maintain workers' compensation and commercial general liability insurance, comply with E-Verify requirements, and accept a three-month probationary termination clause. The contract carries a two-year initial term with an option for one-year renewal and is potentially funded through FEMA, triggering additional federal compliance obligations including adherence to the Clean Air Act and Federal Water Pollution Control Act. The mismatch between the code's pharmaceutical scope and the actual naloxone procurement suggests either a coding error in the state or local procurement system or that this code is used inconsistently across jurisdictions for broader harm-reduction and public health product categories.